🚀 VC round data is live in beta, check it out!
Bionano Genomics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bionano Genomics and similar public comparables like Spineguard, Observe Medical, Trinity Biotech, Arcoma and more.
Bionano Genomics Overview
About Bionano Genomics
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Founded
2007
HQ
Employees
100
Website
Financials (LTM)
EV
$956K
Bionano Genomics Financials
Bionano Genomics reported last 12-month revenue of $30M.
In the same LTM period, Bionano Genomics generated $14M in gross profit and had net loss of ($27M).
Revenue (LTM)
Bionano Genomics P&L
In the most recent fiscal year, Bionano Genomics reported revenue of $29M and EBITDA of ($16M).
Bionano Genomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $30M | XXX | $29M | XXX | XXX | XXX |
| Gross Profit | $14M | XXX | $13M | XXX | XXX | XXX |
| Gross Margin | 48% | XXX | 46% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($16M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (57%) | XXX | XXX | XXX |
| EBIT Margin | (109%) | XXX | (117%) | XXX | XXX | XXX |
| Net Profit | ($27M) | XXX | ($26M) | XXX | XXX | XXX |
| Net Margin | (92%) | XXX | (93%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bionano Genomics Stock Performance
Bionano Genomics has current market cap of $13M, and enterprise value of $956K.
Market Cap Evolution
Bionano Genomics' stock price is $1.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $956K | $13M | 5.3% | XXX | XXX | XXX | $-2.38 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBionano Genomics Valuation Multiples
Bionano Genomics trades at 0.0x EV/Revenue multiple, and (0.1x) EV/EBITDA.
EV / Revenue (LTM)
Bionano Genomics Financial Valuation Multiples
As of April 8, 2026, Bionano Genomics has market cap of $13M and EV of $956K.
Equity research analysts estimate Bionano Genomics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bionano Genomics has a P/E ratio of (0.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13M | XXX | $13M | XXX | XXX | XXX |
| EV (current) | $956K | XXX | $956K | XXX | XXX | XXX |
| EV/Revenue | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.1x) | XXX | XXX | XXX |
| EV/EBIT | (0.0x) | XXX | (0.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| P/E | (0.5x) | XXX | (0.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bionano Genomics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bionano Genomics Margins & Growth Rates
Bionano Genomics' revenue in the last 12 month grew by 21%.
Bionano Genomics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.5M for the same period.
Bionano Genomics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (57%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (83%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 38% | XXX | 40% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 163% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Bionano Genomics Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Spineguard | XXX | XXX | XXX | XXX | XXX | XXX |
| Observe Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Trinity Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcoma | XXX | XXX | XXX | XXX | XXX | XXX |
| Polyrizon | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bionano Genomics M&A Activity
Bionano Genomics acquired XXX companies to date.
Last acquisition by Bionano Genomics was on XXXXXXXX, XXXXX. Bionano Genomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Bionano Genomics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBionano Genomics Investment Activity
Bionano Genomics invested in XXX companies to date.
Bionano Genomics made its latest investment on XXXXXXXX, XXXXX. Bionano Genomics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Bionano Genomics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bionano Genomics
| When was Bionano Genomics founded? | Bionano Genomics was founded in 2007. |
| Where is Bionano Genomics headquartered? | Bionano Genomics is headquartered in United States. |
| How many employees does Bionano Genomics have? | As of today, Bionano Genomics has over 100 employees. |
| Who is the CEO of Bionano Genomics? | Bionano Genomics' CEO is R. Erik Holmlin. |
| Is Bionano Genomics publicly listed? | Yes, Bionano Genomics is a public company listed on Nasdaq. |
| What is the stock symbol of Bionano Genomics? | Bionano Genomics trades under BNGO ticker. |
| When did Bionano Genomics go public? | Bionano Genomics went public in 2018. |
| Who are competitors of Bionano Genomics? | Bionano Genomics main competitors are Spineguard, Observe Medical, Trinity Biotech, Arcoma. |
| What is the current market cap of Bionano Genomics? | Bionano Genomics' current market cap is $13M. |
| What is the current revenue of Bionano Genomics? | Bionano Genomics' last 12 months revenue is $30M. |
| What is the current revenue growth of Bionano Genomics? | Bionano Genomics revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Bionano Genomics? | Current revenue multiple of Bionano Genomics is 0.0x. |
| Is Bionano Genomics profitable? | No, Bionano Genomics is not profitable. |
| What is the current net income of Bionano Genomics? | Bionano Genomics' last 12 months net income is ($27M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.